Our site uses cookies to make navigation as functional as possible, including "third party" cookies and "profiling cookies" designed to tailor on-line contents to suit the preferences expressed while surfing the internet. Should you wish to receive more information, or deny your consent to some or all cookies, click here. If you proceed browsing this website, you will be consenting to the use of all cookies.
More info
itaeng
Home

Latest News

Jan 22 2021
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) Awareness Day
23 rd January 2021 marks the second annual BPDCN Awareness Day (#BPDCNday) since it received its own classification as a distinct hematologic maligna...
Jan 21 2021
Menarini Receives European Commission Approval of ELZONRIS (tagraxofusp), for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
ELZONRIS is the first approved treatment for patients with BPDCN, and the first approved CD123-targeted therapy, in Europe.
Dec 16 2020
Menarini Group awarded the coveted XV Transatlantic Award from American Chamber of Commerce in Italy
READ ALL NEWS »

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) Awareness Day

23 rd January 2021 marks the second annual BPDCN Awareness Day (#BPDCNday) since it received its own classification as a distinct hematologic malignancy by the World Health Organization (WHO).
Read more

Company Video Menarini

MENARINI PILLS OF ART

Concession granted by Italian Ministry for Cultural Heritage and Activities Read more